Key facts
- It has raised $1.1M across 1 recorded rounds; the latest was Seed Round ($1.1M) in Mar 2026.
- Notable investors include WaterStar Capital.
- OpZira has filed 1 Form D with the SEC, most recently Mar 2026 ($1.1M sold to 6 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for OpZira
Funding rounds
1 roundsAbout OpZira
Manufacturer of advanced ocular disease detection and monitoring systems designed to preserve vision and improve patients' quality of life. The company develops advanced, innovative diagnostic technologies for individuals affected by ocular diseases through precision diagnostics and continuous disease management support, enabling clinicians to identify eye disorders at earlier stages and monitor disease progression more effectively.
- Sector
- Healthcare
- HQ
- Middletown, PA, United States
- Founded
- 2025
- Employees
- 14
- Website
- opzira.com/
- Ownership
- Privately Held (backing)
OpZira doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OpZira shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OpZira in its N-PORT filings yet. We sweep new filings monthly.